Vera Marisa Costa is an expert in Toxicology at University of Porto (Portugal). As of October 2026, ScienceLeadR ranks Vera Marisa Costa in the top 1% of experts in Portugal for Cardiotoxicity. Vera Marisa Costa has authored 170 publications, the most recent in 2026. SLR score: 497 (community average: 125). How the SLR is computed.

LeadR Profile

Vera Marisa Costa University of Porto Portugal
497 ScienceLeadR Reputation 497
Network Map

Toxicology

Subspecialties: Biochemistry - Public Health - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026

Source: PubMed

University of Porto

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Decoupling Neuroprotection from MAO Inhibition via Indane-to-Azaindane Bioisosteric Replacement of Rasagiline.
PMID 42866009 — neuroprotection, bioisosterism
ACS Med Chem Lett20260
Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023.
PMID 42814432 — heart diseases, heart failure, heart, cardiovascular diseases, public health, global burden of disease, prevalence, cost of illness, chagas disease
JAMA Cardiol20260
Dual-Acting Vitamin B 3-Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D 2 Receptors with Neuroprotective Activity.
PMID 42312436 — msh release-inhibiting hormone, niacinamide, vitamins, pharmaceutical preparations, dopamine, neuropeptides, therapeutics
J Med Chem20260
Discovery of bridged melanostatin derivatives as potent allosteric modulators of the dopamine D 2 receptors with improved permeability.
PMID 42284887 — msh release-inhibiting hormone, dopamine, drug therapy, research, therapeutics
Biomed Pharmacother20260
Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
PMID 41785894 — mortality, breast neoplasms, incidence, neoplasms, income, global burden of disease, breast, prevalence, risk factors, cost of illness
Lancet Oncol Top journal20262

LeadR Networks

Main global connection map